Covid Boosters are proving to be not only a health disaster but a financial one too.
In the past week Pfizer’s CEO, Andrew Bourla, has said that the company now expects 2023 revenues of $58 to $61 bn, down from previous estimates of $67 to $70 bn.
This slashing of full-year earnings and revenue guidance comes as Covid vaccine sales slump.
Essentially the rollout of Pfizer’s latest Covid booster has been rocky, and prior vaccination and infection has made cases milder than before for many people. This past week, Pfizer have admitted that a huge majority of Americans—some 80 percent—have rejected taking the latest COVID booster shot.
One difficulty of the vaccines is that they only proved to be effective for a short time with a sharply declining effectiveness over three to six months. Hence the need for a booster in the first place.
People who refused the jab and contracted and beat Covid without treatment have enjoyed longer lasting protection from subsequent severe Covid incidents. A case of natural immunity proving superior to vaccine acquired immunity.
Said individuals also avoided the side effects, including severe side effects, reported by some of those who had taken the Covid shots. Many who took the shots and experienced side effects have led them to refuse further jabs.
Covid vaccines, for example, have been decisively linked to myocarditis, a kind of heart inflammation, especially in teens and young adult males who were near zero risk of serious effects from the Covid virus itself.
Many individuals and researchers have come to view mRNA technology as a highly problematic and dangerous gene-level medical treatment that can cause devastating reactions in the human body. It was an unprecedented medical experiment with no medium or long term safety data. Moderna, another mRNA COVID treatment company, has called the technology a genetic “software” for programming human genetics.
Most went along with it due to the ubiquitous propaganda, whereby to take the words of Matt Hancock (British Health Secretary), we need to “frighten the pants of everyone”. Now the pandemic is over and people have had a chance to gather their thoughts and reflect upon experience.
To put it simply, for a range of reasons, people are increasingly saying no to the Covid shots.
In addition, other non-mRNA COVID treatments peddled by Pfizer are also doing poorly. For example, sales of Paxlovid are expected to be $7 billion lower than previously estimated. This has also taken a hit on Pfizer’s stock which are now estimated to be $1.45 to $1.65 per share, in contrast to previous estimates of $3.25 to $3.45 per share.
Ed Dowd's Telegram page showing collapse in Pfizer shares
Same source showing collapse in Moderna's shares
Say no to mandates
The campaign against mandated vaccinations for health care workers in New York had a victory this month when the court refused an appeal to overturn the January ruling.
In further news the US Defence Department reached an agreement to settle two lawsuits against the military-wide vaccine mandate. Agreeing to pay out $1.8 million.
Although it was the Navy SEAL plaintiffs who filed their complaint in October 2021 after President Joe Biden ordered that all U.S. servicemen and other members of the executive branch receive the COVID-19 vaccine. The suits represented plaintiffs from all branches of the military.
Gates Still Pushing and Profiting From Controversial Gene Level mRNA Treatments.
Even as people in the West may be over COVID and its notorious mRNA treatments, Bill Gates isn’t. Gates is again plumbing the depths, by peddling mRNA treatments to developing regions, primarily Africa.
People in many parts of Africa have less access to information via ready internet connections, to gain awareness concerning the controversies surrounding mRNA medical technologies. Meanwhile, the Bill & Melinda Gates Foundation is putting $40 million into a wide-ranging mRNA push. It envisions the technology to be used for “vaccine treatments” of infectious diseases including tuberculosis, malaria, and Lassa fever, among other maladies.
